Dr. Marshall Discusses Frontline Treatment for CRC

John L. Marshall, MD
Published: Friday, Dec 22, 2017



John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses frontline treatment options for patients with colorectal cancer (CRC).

According to Marshall, when determining treatment for patients with metastatic CRC depending on the location of the tumor, it is important to know the molecular testing. Knowing if the patient is microsatellite stable (MSS) or microsatellite instable (MSI) could affect treatment decisions.

If a patient has right-sided CRC, it appears that EGFR-targeted therapies do not work well in the frontline space, explains Marshall.
 
SELECTED
LANGUAGE


John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses frontline treatment options for patients with colorectal cancer (CRC).

According to Marshall, when determining treatment for patients with metastatic CRC depending on the location of the tumor, it is important to know the molecular testing. Knowing if the patient is microsatellite stable (MSS) or microsatellite instable (MSI) could affect treatment decisions.

If a patient has right-sided CRC, it appears that EGFR-targeted therapies do not work well in the frontline space, explains Marshall.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x